Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of BI 764532 plus ezabenlimab in DLL3-positive small cell lung carcinoma and other neuroendocrine neoplasms
jRCT2031220716Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of obrixtamig and ezabenlimab in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine carcinoma (NEC) and 2 more, sponsored by Boehringer Ingelheim. Primary endpoint: Dose-limiting toxicities within the MTD evaluation period. Started Jun 2023; status: completed.
02
Drugs
obrixtamigezabenlimab
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine carcinoma (NEC)small cell carcinoma (SCC)apudoma (NET)
Beyond the preview
Go deeper on jRCT2031220716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220716.